BLAINTRAMUSCULARINJECTION, SUSPENSION1 Generic Approved
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 7h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
mNEXSPIKE is a Moderna mRNA-based COVID-19 vaccine administered as an intramuscular injection. It represents a next-generation formulation in the mRNA vaccine class designed to provide immunization against SARS-CoV-2. The vaccine leverages mRNA technology to instruct cells to produce viral spike proteins, triggering an immune response.
Growth
Recent launch status indicates active team expansion and growth-phase hiring across commercial, manufacturing, and regulatory functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Moderna is hiring 1 role related to this product
Worked on mNEXSPIKE at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.